Caris’ Precision Oncology Alliance Welcomes University of Iowa Holden Comprehensive Cancer Center

IRVING, Texas, November 16, 2022 – Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced today that University of Iowa Holden Comprehensive Cancer Center has joined Caris’ Precision Oncology Alliance™ (POA).

The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients.

Holden Cancer Center is Iowa's only NCI-designated comprehensive cancer center, and has held that designation since 2000. Nearly 1,200 staff and cancer center members, including faculty from 41 academic departments, collaborate to drive Holden's research, education, and patient-care missions. Holden is the recipient of two NCI Specialized Program of Research Excellence (SPORE) grants, including the first and only neuroendocrine tumor SPORE.

“We are excited about joining forces with experts from around the country as members of this important alliance that is based on the understanding that progress in cancer research is accelerated when we work together,” said George Weiner, M.D., Director of Holden Comprehensive Cancer Center.

“We’re pleased to welcome Holden Cancer Center into the growing Caris Precision Oncology Alliance network,” said Chadi Nabhan, M.D., MBA, FACP, Chairman of the Caris Precision Oncology Alliance. “Collaborating with top researchers, investigators, and physicians at the University of Iowa Cancer Center will lead to more cutting-edge precision oncology research that is destined to improve outcomes of all patients affected with cancer.”

The Caris Precision Oncology Alliance includes 74 cancer centers and academic institutions. These institutions have early access to the extensive database and artificial intelligence platform within Caris to establish evidence-based standards for cancer profiling and advance research in cancer precision medicine. By leveraging the comprehensive genomic, transcriptomic and proteomic profiling available through Caris molecular profiling, Caris seeks to provide this network with the ability to prioritize therapeutic options and determine which clinical trial opportunities may benefit their patients. POA members are also able to integrate with a growing portfolio of biomarker directed trials sponsored by biopharma. Additionally, as a member of the POA, institutions have access to Caris CODEai™, the most comprehensive data solution in the industry with cancer treatment information and clinical outcomes data for over 275,000 patients covering over 1 million data points per patient.